Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have been a major advance in the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) which have been substantiated in clinical trials. However, real-world data on first-line alectinib in a Chinese patient population...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Zihua, Gu, Yangchun, Liang, Li, Hao, Xuezhi, Fan, Chengjuan, Xin, Tao, Zhao, Songchen, Liu, Ziling, Guo, Ye, Ma, Kewei, Li, Haojing, Zhang, Cuiying, Shan, Li, Zhang, Yan, Dong, Guilan, Peng, Yumei, Shen, Fangfang, Song, Xia, Christopoulos, Petros, van der Wekken, Anthonie J., Okuda, Katsuhiro, Ekman, Simon, Xing, Puyuan, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830268/
https://www.ncbi.nlm.nih.gov/pubmed/36636411
http://dx.doi.org/10.21037/tlcr-22-803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830268/
https://www.ncbi.nlm.nih.gov/pubmed/36636411
http://dx.doi.org/10.21037/tlcr-22-803

Ejemplares similares